PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53원문보기
Liu, Qi
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Gheorghiu, Liliana
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Drumm, Michael
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Clayman, Rebecca
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Eidelman, Alec
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Wszolek, Matthew F.
(Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Olumi, Aria
(Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Feldman, Adam
(Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Wang, Meng
(Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts)
,
Marcar, Lynnette
(Departm)
,
Citrin, Deborah E.
,
Wu, Chin-Lee
,
Benes, Cyril H.
,
Efstathiou, Jason A.
,
Willers, Henning
Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive b...
Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive bladder cancer (MIBC), which has poor therapeutic outcomes. We assessed the DNA damaging and cytotoxic effects of the PARPi olaparib in nine bladder cancer cell lines. Olaparib radiosensitized all cell lines with dose enhancement factors from 1.22 to 2.27. Radiosensitization was correlated with the induction of potentially lethal DNA double-strand breaks (DSB) but not with RAD51 foci formation. The ability of olaparib to radiosensitize MIBC cells was linked to the extent of cell kill achieved with drug alone. Unexpectedly, increased levels of reactive oxygen species (ROS) resulting from PARPi treatment were the cause of DSB throughout the cell cycle in-vitro and in-vivo. ROS originated from mitochondria and were required for the radiosensitizing effects of olaparib. Consistent with the role of TP53 in ROS regulation, loss of p53 function enhanced radiosensitization by olaparib in non-isogenic and isogenic cell line models and was associated with increased PARP-1 expression in bladder cancer cell lines and tumors. Impairment of ATM in addition to p53 loss resulted in an even more pronounced radiosensitization. In conclusion, ROS suppression by PARP-1 in MIBC is a potential therapeutic target either for PARPi combined with radiation or drug alone treatment. The TP53 and ATM genes, commonly mutated in MIBC and other cancers, are candidate biomarkers of PARPi-mediated radiosensitization.
Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive bladder cancer (MIBC), which has poor therapeutic outcomes. We assessed the DNA damaging and cytotoxic effects of the PARPi olaparib in nine bladder cancer cell lines. Olaparib radiosensitized all cell lines with dose enhancement factors from 1.22 to 2.27. Radiosensitization was correlated with the induction of potentially lethal DNA double-strand breaks (DSB) but not with RAD51 foci formation. The ability of olaparib to radiosensitize MIBC cells was linked to the extent of cell kill achieved with drug alone. Unexpectedly, increased levels of reactive oxygen species (ROS) resulting from PARPi treatment were the cause of DSB throughout the cell cycle in-vitro and in-vivo. ROS originated from mitochondria and were required for the radiosensitizing effects of olaparib. Consistent with the role of TP53 in ROS regulation, loss of p53 function enhanced radiosensitization by olaparib in non-isogenic and isogenic cell line models and was associated with increased PARP-1 expression in bladder cancer cell lines and tumors. Impairment of ATM in addition to p53 loss resulted in an even more pronounced radiosensitization. In conclusion, ROS suppression by PARP-1 in MIBC is a potential therapeutic target either for PARPi combined with radiation or drug alone treatment. The TP53 and ATM genes, commonly mutated in MIBC and other cancers, are candidate biomarkers of PARPi-mediated radiosensitization.
1 Ameziane-El-Hassani R Dupuy C Detection of Intracellular Reactive Oxygen Species (CM-H2DCFDA) Bio-protocol 2013 3 e313
2 Audebert M Salles B Calsou P Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining J Biol Chem 2004 279 55117 55126 15498778
3 Bai P Canto C Oudart H Brunyanszki A Cen Y Thomas C PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation Cell Metab 2011 13 461 468 21459330
4 Birkelbach M Ferraiolo N Gheorghiu L Pfäffle HN Daly B Ebright M Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues J Thorac Oncol 2013 8 279 286 23399959
5 Brenner JC Ateeq B Li Y Yocum AK Cao Q Asangani IA Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 2011 19 664 678 21575865
6 Bridges KA Toniatti C Buser CA Liu H Buchholz TA Meyn RE Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells Oncotarget 2014 5 5076 5086 24970803
7 Bryant HE Schultz N Thomas HD Parker KM Flower D Lopez E Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005 434 913 917 15829966
8 Bryant HE Helleday T Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair Nucleic Acids Res 2006 34 1685 1691 16556909
9 Bryant HE Petermann E Schultz N Jemth AS Loseva O Issaeva N PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination EMBO J 2009 28 2601 2615 19629035
10 Cancer Genome Atlas Research N Comprehensive molecular characterization of urothelial bladder carcinoma Nature 2014 507 315 322 24476821
11 Cerami E Gao J Dogrusoz U Gross BE Sumer SO Aksoy BA The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2012 2 401 404 22588877
12 Chalmers AJ Lakshman M Chan N Bristow RG Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets Semin Radiat Oncol 2010 20 274 281 20832020
13 Chan N Pires IM Bencokova Z Coackley C Luoto KR Bhogal N Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment Cancer Res 2010 70 8045 8054 20924112
14 Coleman CN Higgins GS Brown JM Baumann M Kirsch DG Willers H Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials Clin Cancer Res 2016 22 3138 3147 27154913
15 Deschenes F Massip L Garand C Lebel M In vivo misregulation of genes involved in apoptosis, development and oxidative stress in mice lacking both functional Werner syndrome protein and poly(ADP-ribose) polymerase-1 Hum Mol Genet 2005 14 3293 3308 16195394
16 Dulaney C Marcrom S Stanley J Yang ES Poly(ADP-ribose) polymerase activity and inhibition in cancer Semin Cell Dev Biol 2017
17 Engert F Schneider C Weibeta LM Probst M Fulda S PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway Mol Cancer Ther 2015 14 2818 2830 26438158
18 Farmer H McCabe N Lord CJ Tutt AN Johnson DA Richardson TB Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 917 921 15829967
19 Feng FY de Bono JS Rubin MA Knudsen KE Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function Mol Cell 2015 58 925 934 26091341
20 Gani C Coackley C Kumareswaran R Schutze C Krause M Zafarana G In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio Radiother Oncol 2015 116 486 494 26277432
21 Gibson BA Kraus WL New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nat Rev Mol Cell Biol 2012 13 411 424 22713970
22 Gorrini C Harris IS Mak TW Modulation of oxidative stress as an anticancer strategy Nat Rev Drug Discov 2013 12 931 947 24287781
23 Han D Williams E Cadenas E Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space Biochem J 2001 353 411 416 11139407
24 Hempel N Ye H Abessi B Mian B Melendez JA Altered redox status accompanies progression to metastatic human bladder cancer Free Radic Biol Med 2009 46 42 50 18930813
25 Ireno IC Wiehe RS Stahl AI Hampp S Aydin S Troester MA Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53 Carcinogenesis 2014 35 2273 2282 25085902
26 Kamat AM Hahn NM Efstathiou JA Lerner SP Malmstrom PU Choi W Bladder cancer Lancet 2016 388 2796 2810 27345655
27 Kamsler A Daily D Hochman A Stern N Shiloh Y Rotman G Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice Cancer Res 2001 61 1849 1854 11280737
28 Kotter A Cornils K Borgmann K Dahm-Daphi J Petersen C Dikomey E Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells Mol Oncol 2014 8 1616 1625 25028150
29 Lamy A Gobet F Laurent M Blanchard F Varin C Moulin C Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations J Urol 2006 176 2686 2689 17085196
30 Lee HJ Yoon C Schmidt B Park DJ Zhang AY Erkizan HV Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage Mol Cancer Ther 2013 12 2591 2600 23966622
31 Lee JS Leem SH Lee SY Kim SC Park ES Kim SB Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors J Clin Oncol 2010 28 2660 2667 20421545
32 Liu Q Ghosh P Magpayo N Testa M Tang S Gheorghiu L Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation Int J Radiat Oncol Biol Phys 2015 91 1081 1089 25832698
33 Liu Q Wang M Kern AM Khaled S Han J Yeap BY Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers Mol Cancer Res 2015 13 713 720 25667133
34 Liu Q Wang M Kern AM Khaled S Han J Yeap BY Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers Mol Cancer Res 2015 13 713 720 25667133
36 Martin-Cordero C Leon-Gonzalez AJ Calderon-Montano JM Burgos-Moron E Lopez-Lazaro M Pro-oxidant natural products as anticancer agents Curr Drug Targets 2012 13 1006 1028 22594470
37 Michels J Vitale I Saparbaev M Castedo M Kroemer G Predictive biomarkers for cancer therapy with PARP inhibitors Oncogene 2014 33 3894 3907 24037533
38 Mukhopadhyay P Rajesh M Yoshihiro K Hasko G Pacher P Simple quantitative detection of mitochondrial superoxide production in live cells Biochem Biophys Res Commun 2007 358 203 208 17475217
40 Nisimoto Y Diebold BA Cosentino-Gomes D Lambeth JD Nox4: a hydrogen peroxide-generating oxygen sensor Biochemistry 2014 53 5111 5120 25062272
41 Paxinou E Weisse M Chen Q Souza JM Hertkorn C Selak M Dynamic regulation of metabolism and respiration by endogenously produced nitric oxide protects against oxidative stress Proc Natl Acad Sci U S A 2001 98 11575 11580 11562476
42 Pommier Y O'Connor MJ de Bono J Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action Sci Transl Med 2016 8 362ps317
43 Rhodes DR Yu J Shanker K Deshpande N Varambally R Ghosh D ONCOMINE: a cancer microarray database and integrated data-mining platform Neoplasia 2004 6 1 6 15068665
45 Rossi MN Carbone M Mostocotto C Mancone C Tripodi M Maione R Mitochondrial localization of PARP-1 requires interaction with mitofilin and is involved in the maintenance of mitochondrial DNA integrity J Biol Chem 2009 284 31616 31624 19762472
46 Sablina AA Budanov AV Ilyinskaya GV Agapova LS Kravchenko JE Chumakov PM The antioxidant function of the p53 tumor suppressor Nat Med 2005 11 1306 1313 16286925
47 Senra JM Telfer BA Cherry KE McCrudden CM Hirst DG O'Connor MJ Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft Mol Cancer Ther 2011 10 1949 1958 21825006
48 Strom CE Johansson F Uhlen M Szigyarto CA Erixon K Helleday T Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate Nucleic Acids Res 2011 39 3166 3175 21183466
49 Trachootham D Alexandre J Huang P Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009 8 579 591 19478820
50 Van Allen EM Mouw KW Kim P Iyer G Wagle N Al-Ahmadie H Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Cancer Discov 2014 4 1140 1153 25096233
51 Verhagen CV de Haan R Hageman F Oostendorp TP Carli AL O'Connor MJ Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells Radiother Oncol 2015 116 358 365 25981132
52 Wang M Morsbach F Sander D Gheorghiu L Nanda A Benes C EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks Cancer Res 2011 71 6261 6269 21852385
53 Wang M Kern AM Hulskotter M Greninger P Singh A Pan Y EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation Cancer Res 2014 74 2825 2834 24648348
54 Wurster S Hennes F Parplys AC Seelbach JI Mansour WY Zielinski A PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response Oncotarget 2016 7 9732 9741 26799421
※ AI-Helper는 부적절한 답변을 할 수 있습니다.